Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abcellera Biologics Inc
(NQ:
ABCL
)
4.200
+0.350 (+9.09%)
Streaming Delayed Price
Updated: 10:37 AM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abcellera Biologics Inc
< Previous
1
2
3
4
Next >
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
February 23, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
February 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
February 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
February 10, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
January 27, 2022
From
AbCellera
Via
Business Wire
AbCellera Announces Changes to Its Board of Directors
December 07, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
December 03, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
December 02, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2021 Business Results
November 09, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Virtual Presentations at Investor Conferences in November
November 04, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
November 02, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
October 14, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
September 22, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
September 21, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
September 16, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
September 15, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
September 13, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
September 10, 2021
From
AbCellera
Via
Business Wire
AbCellera Reports Q2 2021 Business Results
August 12, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
August 04, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
August 03, 2021
From
Tachyon Therapeutics, Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
July 22, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Appoints Neil Berkley as Chief Business Officer
July 13, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
June 22, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
June 10, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
May 14, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2021 Business Results
May 13, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
May 11, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
May 06, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
May 04, 2021
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.